Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 0.1 below Eli Lilly's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 426 other companies have achieved higher Quick Ratio than Eli Lilly in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 3195, from total ranking in the second quarter 2026 at 3516.

Explain Quick Ratio?
How much Cash & cash equivalents LLY�s has?
What are LLY�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/LLY/financial-strength

https://api.csimarket.com/api/v1/companies/LLY/fundamentals

https://api.csimarket.com/api/v1/companies/LLY/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

LLY Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	108.68 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-50.72 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.1	Subscribe	Subscribe	Subscribe	Subscribe
LLY's Total Ranking	# 3195	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-1.56 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-45.42 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 427
Healthcare Sector	# 856
Overall Market	# 3783

Quick Ratio Statistics
High	Average	Low
2.73	0.61	0.02
(Mar 31 2016)

Financial Statements
Eli Lilly's Current Liabilities	$ 46,996 Millions	Visit LLY's Balance sheet
Eli Lilly's Cash & cash equivalent	$ 4,885 Millions	Visit LLY's Balance sheet
Source of LLY's Sales		Visit LLY's Sales by Geography

Cumulative Eli Lilly's Quick Ratio

LLY's Quick Ratio for the trailling 12 Months

LLY Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	21.43 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	30.95 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.2	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2973	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	22.83 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-16.01 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to LLY Financial Strength Comparisons >> Go to Compare LLY Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2026 to $46,996.00 millions, cumulative Quick Ratio decreased to 0.2 below the Eli Lilly And Company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Eli Lilly. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2026 at 4169.

Explain Quick Ratio?
How much Cash & cash equivalents LLY�s has?
What are LLY�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 444
Healthcare Sector	# 910
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.87	0.43	0.11
(March 31. 2011)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Phibro Animal Health Corporation	0.28	$ 83.123 Millions	$ 295.787 Millions
Viatris Inc	0.28	$ 1,859.100 Millions	$ 6,636.500 Millions
Prestige Consumer Healthcare Inc	0.28	$ 46.515 Millions	$ 168.503 Millions
Abbott Laboratories	0.27	$ 4,298.000 Millions	$ 16,152.000 Millions
Teva Pharmaceutical Industries Limited	0.26	$ 4,085.000 Millions	$ 15,425.000 Millions
Heron Therapeutics Inc	0.26	$ 23.449 Millions	$ 89.848 Millions
Elanco Animal Health Incorporated	0.26	$ 465.000 Millions	$ 1,787.000 Millions
Abbvie Inc	0.25	$ 10,774.000 Millions	$ 43,102.000 Millions
Collegium Pharmaceutical Inc	0.24	$ 144.797 Millions	$ 603.085 Millions
Indivior Pharmaceuticals Inc	0.23	$ 305.000 Millions	$ 1,301.000 Millions
Igc Pharma Inc	0.13	$ 0.413 Millions	$ 3.143 Millions
Eli Lilly And Company	0.10	$ 4,885.000 Millions	$ 46,996.000 Millions
Amneal Pharmaceuticals Inc	0.08	$ 157.399 Millions	$ 1,946.837 Millions
Protagenic Therapeutics Inc new	0.07	$ 0.077 Millions	$ 1.153 Millions
Provectus Biopharmaceuticals Inc	0.04	$ 0.181 Millions	$ 4.169 Millions
Oramed Pharmaceuticals Inc	0.04	$ 0.583 Millions	$ 13.609 Millions

Date modified: 2026-10-30T13:15:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.